Actualités et Activités de Innovation Pharmaceuticals
Dirigeants
Voir l'organigramme avec ses 4 principaux dirigeants
Biographies les plus recherchées chez Innovation Pharmaceuticals
- Leo Ehrlich, Chief Executive Officer, Chief Financial Officer and...
- Zorik Spektor, Independent Board Member
- Barry Schechter, Independent Board Member
Créer une alerte
pour suivre les mouvements de dirigeants chez Innovation Pharmaceuticals.
Biotechnologie
Innovation Pharmaceuticals a 2 431 concurrents dont Lonza (Suisse), Vertex Pharmaceuticals (Etats—Unis) et Eurofins (Luxembourg).
Actualités en fusion/acquisition en Biotechnologie.
- AdvanCell vient d'annoncer une levée de fonds de 315 millions de dollars. (publié le 21 juillet 2026).
- Allotera Therapeutics vient d'annoncer une levée de fonds de 35 millions de dollars. (publié le 21 juillet 2026).
- Draig Therapeutics vient d'annoncer une levée de fonds de 65 millions de dollars. (publié le 21 juillet 2026).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Innovation Pharmaceuticals
- Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024 — Innovation Pharmaceuticals Inc.
- Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases — Innovation Pharmaceuticals Inc.
- Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing — Innovation Pharmaceuticals Inc.
- Innovation Pharmaceuticals’ Brilacidin Antifungal Research Published in Nature Communications — Innovation Pharmaceuticals Inc.
- Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers — Innovation Pharmaceuticals Inc.
- Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission — Innovation Pharmaceuticals Inc.
- Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement — Innovation Pharmaceuticals Inc.
- Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis — Innovation Pharmaceuticals Inc.
- Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family — Innovation Pharmaceuticals Inc.
- Scientific Poster on Innovation Pharmaceuticals’ Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference — Innovation Pharmaceuticals Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Innovation Pharmaceuticals
- Innovation Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Innovation Pharmaceuticals sur LinkedIn, X (Twitter) & YouTube en 1-click
